Fingolimod suppresses bone resorption in female patients with multiple sclerosis.
Fingolimod is a sphingosine-1-phosphate receptor agonist used to inhibit the inflammatory activity of multiple sclerosis (MS), and has been shown to suppress osteoporosis in mouse models. In this study, levels of bone turnover markers were quantified in serum and urine samples from MS patients treated with fingolimod. Compared with untreated MS patients and healthy controls, fingolimod-treated MS patients had a significantly lower level of the bone resorption marker type I collagen cross-linked N-telopeptide in urine. This finding was prominent in female but was not seen in male subjects. Our results suggest that fingolimod may have a beneficial effect on bone mass loss in female MS patients.
Department of Clinical Research, Hokkaido Medical Center, 1-1 Yamanote 5-jo 7-chome, Nishi-ku, Sapporo 063-0005, Japan; Department of Neurology, Hokkaido Medical Center, 1-1 Yamanote 5-jo 7-chome, Nishi-ku, Sapporo 063-0005, Japan. Electronic address: yuseimiyazaki@hok-mc.hosp.go.jp.
Yusei
Y
Miyazaki
Department of Clinical Research, Hokkaido Medical Center, 1-1 Yamanote 5-jo 7-chome, Nishi-ku, Sapporo 063-0005, Japan.
Masaaki
M
Niino
Department of Internal Medicine 1, Shimane University Faculty of Medicine, 89-1 Enyacho, Izumo 693-8501, Japan.
Ippei
I
Kanazawa
Division of Neurology and Gerontology, Department of Internal Medicine, Iwate Medical University, 19-1 Uchimaru, Morioka 020-8505, Japan.
Masako
M
Suzuki
Division of Neurology and Gerontology, Department of Internal Medicine, Iwate Medical University, 19-1 Uchimaru, Morioka 020-8505, Japan.
Masanori
M
Mizuno
Department of Neurology, Sapporo Medical University School of Medicine, Minami-1-jo Nishi-17-chome, Chuo-ku, Sapporo 060-8556, Japan.
Shin
S
Hisahara
Sapporo Neurology Clinic, 2-17 Kita-21-jo Higashi-21-chome, Higashi-ku, Sapporo 065-0021, Japan.
Toshiyuki
T
Fukazawa
Department of Clinical Research, Hokkaido Medical Center, 1-1 Yamanote 5-jo 7-chome, Nishi-ku, Sapporo 063-0005, Japan.
Eri
E
Takahashi
Department of Neurology, Hokkaido Medical Center, 1-1 Yamanote 5-jo 7-chome, Nishi-ku, Sapporo 063-0005, Japan.
Itaru
I
Amino
Department of Neurology, Hokkaido Medical Center, 1-1 Yamanote 5-jo 7-chome, Nishi-ku, Sapporo 063-0005, Japan.
Ryutaro
R
Ochi
Department of Neurology, Hokkaido Medical Center, 1-1 Yamanote 5-jo 7-chome, Nishi-ku, Sapporo 063-0005, Japan.
Masakazu
M
Nakamura
Department of Neurology, Hokkaido Medical Center, 1-1 Yamanote 5-jo 7-chome, Nishi-ku, Sapporo 063-0005, Japan.
Sachiko
S
Akimoto
Department of Neurology, Hokkaido Medical Center, 1-1 Yamanote 5-jo 7-chome, Nishi-ku, Sapporo 063-0005, Japan.
Naoya
N
Minami
Department of Neurology, Hokkaido Medical Center, 1-1 Yamanote 5-jo 7-chome, Nishi-ku, Sapporo 063-0005, Japan.
Naoto
N
Fujiki
Department of Neurology, Hokkaido Medical Center, 1-1 Yamanote 5-jo 7-chome, Nishi-ku, Sapporo 063-0005, Japan.
Shizuki
S
Doi
Department of Neurology, Sapporo Medical University School of Medicine, Minami-1-jo Nishi-17-chome, Chuo-ku, Sapporo 060-8556, Japan.
Shun
S
Shimohama
Division of Neurology and Gerontology, Department of Internal Medicine, Iwate Medical University, 19-1 Uchimaru, Morioka 020-8505, Japan.
Yasuo
Y
Terayama
Department of Neurology, Hokkaido Medical Center, 1-1 Yamanote 5-jo 7-chome, Nishi-ku, Sapporo 063-0005, Japan.
Seiji
S
Kikuchi
D000328:Adult; D001862:Bone Resorption / Q000188:drug therapy* / Q000209:etiology*; D024042:Collagen Type I / Q000652:urine; D004185:Disability Evaluation; D005260:Female; D000068876:Fingolimod Hydrochloride / Q000627:therapeutic use*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000150:complications* / Q000188:drug therapy / Q000652:urine; D010446:Peptide Fragments / Q000378:metabolism; D010455:Peptides / Q000652:urine; D011347:Procollagen / Q000378:metabolism; D012727:Sex Characteristics; D000071681:Tartrate-Resistant Acid Phosphatase / Q000378:metabolism
D024042:Collagen Type I; D007166:Immunosuppressive Agents; D010446:Peptide Fragments; D010455:Peptides; D011347:Procollagen; C052929:collagen type I trimeric cross-linked peptide; C047202:procollagen Type I N-terminal peptide; C000605510:ACP5 protein, human; D000071681:Tartrate-Resistant Acid Phosphatase; D000068876:Fingolimod Hydrochloride
Bone resorption; Fingolimod; Multiple sclerosis; Osteoclasts; Osteoporosis; Sphingosine-1-phosphate